IBDEI1BM ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23696,0)
 ;;=12.5^1^141^1461^19^-DIABETES MELLITUS^1^1
 ;;^UTILITY(U,$J,358.3,23696,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23696,1,3,0)
 ;;=3
 ;;^UTILITY(U,$J,358.3,23696,1,5,0)
 ;;=5
 ;;^UTILITY(U,$J,358.3,23697,0)
 ;;=64.5^1^141^1461^22^-Dislocation^1^1
 ;;^UTILITY(U,$J,358.3,23697,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23697,1,3,0)
 ;;=3
 ;;^UTILITY(U,$J,358.3,23697,1,5,0)
 ;;=5
 ;;^UTILITY(U,$J,358.3,23698,0)
 ;;=459.10^^141^1461^31
 ;;^UTILITY(U,$J,358.3,23698,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23698,1,3,0)
 ;;=3^459.10
 ;;^UTILITY(U,$J,358.3,23698,1,5,0)
 ;;=5^Post Phlebotic Syndrome
 ;;^UTILITY(U,$J,358.3,23698,2)
 ;;=Post Phlebotic Syndrome^328597
 ;;^UTILITY(U,$J,358.3,23699,0)
 ;;=719.7^^141^1461^21
 ;;^UTILITY(U,$J,358.3,23699,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23699,1,3,0)
 ;;=3^719.7
 ;;^UTILITY(U,$J,358.3,23699,1,5,0)
 ;;=5^Difficulty In Walking
 ;;^UTILITY(U,$J,358.3,23699,2)
 ;;=^329945
 ;;^UTILITY(U,$J,358.3,23700,0)
 ;;=453.40^^141^1461^8
 ;;^UTILITY(U,$J,358.3,23700,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23700,1,3,0)
 ;;=3^453.40
 ;;^UTILITY(U,$J,358.3,23700,1,5,0)
 ;;=5^Deep vein thrombosis lower extremity
 ;;^UTILITY(U,$J,358.3,23700,2)
 ;;=^338554
 ;;^UTILITY(U,$J,358.3,23701,0)
 ;;=357.2^^141^1461^20
 ;;^UTILITY(U,$J,358.3,23701,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23701,1,3,0)
 ;;=3^357.2
 ;;^UTILITY(U,$J,358.3,23701,1,5,0)
 ;;=5^Diabetic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,23701,2)
 ;;=^96321
 ;;^UTILITY(U,$J,358.3,23702,0)
 ;;=250.60^^141^1461^4
 ;;^UTILITY(U,$J,358.3,23702,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23702,1,3,0)
 ;;=3^250.60
 ;;^UTILITY(U,$J,358.3,23702,1,5,0)
 ;;=5^DM II w/ Neuro Manif
 ;;^UTILITY(U,$J,358.3,23702,2)
 ;;=^331803
 ;;^UTILITY(U,$J,358.3,23703,0)
 ;;=250.70^^141^1461^6
 ;;^UTILITY(U,$J,358.3,23703,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23703,1,3,0)
 ;;=3^250.70
 ;;^UTILITY(U,$J,358.3,23703,1,5,0)
 ;;=5^DM II w/ Periph Circ Disorder
 ;;^UTILITY(U,$J,358.3,23703,2)
 ;;=^331807
 ;;^UTILITY(U,$J,358.3,23704,0)
 ;;=250.80^^141^1461^5
 ;;^UTILITY(U,$J,358.3,23704,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23704,1,3,0)
 ;;=3^250.80
 ;;^UTILITY(U,$J,358.3,23704,1,5,0)
 ;;=5^DM II w/ Oth Manif
 ;;^UTILITY(U,$J,358.3,23704,2)
 ;;=^331811
 ;;^UTILITY(U,$J,358.3,23705,0)
 ;;=692.9^^141^1462^1
 ;;^UTILITY(U,$J,358.3,23705,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23705,1,3,0)
 ;;=3^692.9
 ;;^UTILITY(U,$J,358.3,23705,1,5,0)
 ;;=5^Eczema
 ;;^UTILITY(U,$J,358.3,23705,2)
 ;;=^27800
 ;;^UTILITY(U,$J,358.3,23706,0)
 ;;=691.8^^141^1462^2
 ;;^UTILITY(U,$J,358.3,23706,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23706,1,3,0)
 ;;=3^691.8
 ;;^UTILITY(U,$J,358.3,23706,1,5,0)
 ;;=5^Eczema, allergic
 ;;^UTILITY(U,$J,358.3,23706,2)
 ;;=^87342
 ;;^UTILITY(U,$J,358.3,23707,0)
 ;;=782.3^^141^1462^3
 ;;^UTILITY(U,$J,358.3,23707,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23707,1,3,0)
 ;;=3^782.3
 ;;^UTILITY(U,$J,358.3,23707,1,5,0)
 ;;=5^Edema (any site)
 ;;^UTILITY(U,$J,358.3,23707,2)
 ;;=^38340
 ;;^UTILITY(U,$J,358.3,23708,0)
 ;;=726.70^^141^1462^4
 ;;^UTILITY(U,$J,358.3,23708,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23708,1,3,0)
 ;;=3^726.70
 ;;^UTILITY(U,$J,358.3,23708,1,5,0)
 ;;=5^Enthesopathy of ankle & tarsus, unspecified
 ;;^UTILITY(U,$J,358.3,23708,2)
 ;;=^272548
 ;;^UTILITY(U,$J,358.3,23709,0)
 ;;=736.72^^141^1462^5
 ;;^UTILITY(U,$J,358.3,23709,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23709,1,3,0)
 ;;=3^736.72
 ;;^UTILITY(U,$J,358.3,23709,1,5,0)
 ;;=5^Equinus deformity of foot, acquired
